Overview   

Discover how HUGO-GT™ mouse models are cutting-edge tools for preclinical research on gene therapy drugs like ASO, Targeted Gene Editing, siRNA, AAV, and LNP in oncology, immunology, neuroscience, and more.

Cyagen’s HUGO-GT platform enables the creation of full human genomic orthologs for rare diseases, enhancing translation to clinical trials. Using our TurboKnockout ES cell technology, we replace mouse genes with full-length human genes (both wild-type and mutant), generating over 80 different HUGO-GT models for human rare diseases.

Join us for a look at the newest validation data on mouse models for neurodegenerative (SMA, AD, ALS), ophthalmological (RP, CD), and metabolic diseases (ATTR, EB), and learn how to create custom animal models for your research.

REGISTER NOW!

 

 

 

Thursday Dec. 5: 

11 am – 12 pm

NYU Langone Health Science Building G19

 

 

   Who Should Attend?   

• Researchers in oncology, immunology, and neuroscience
• Pharmaceutical scientists involved in drug development
• Clinical researchers focused on gene therapy
• Geneticists interested in rare diseases
• Students in biomedical fields
• Industry professionals in biotech

 

 

   Speaker   

 

Marvin Yingbin Ouyang, MD, PhD 

Executive Vice President and Chief Scientific Officer, Cyagen

 

Before joining Cyagen in 2012, Dr. Ouyang served as a senior scientist at Oklahoma Medical Research Foundation, Thios Pharmaceuticals in the United States, and as Group Leader of the Molecular Biology Department of Taconic Biosciences. Over the past 20 years, he has committed himself to the custom design and generation of genetically engineered mice. While at Cyagen, he has successfully developed thousands of transgenic and gene knockout/knockin mouse and rat models for the biomedical research and drug discovery communities worldwide. He has published many papers in high-level academic journals such as PNAS and JBC; his technical services have been directly cited by Nature and other international journals hundreds of times.

 

 

 

   About Cyagen   

Cyagen Biosciences is a leading Contract Research Organization (CRO) with nearly 20 years of experience, dedicated to accelerating drug discovery and development through the integration of data, algorithms, and advanced modeling techniques. Leveraging our expertise in genetically modified rodent models, we offer comprehensive preclinical services to meet the diverse needs of researchers worldwide. Combining cutting-edge AI technologies with our extensive experience, we provide full-service solutions for target research, virus design and packaging, model construction, and efficacy evaluation. Our mission is to empower researchers across the globe by delivering innovative and intelligent solutions that drive breakthroughs in both fundamental research and drug development.

 

 

 

   About HUGO-GT^TM   

The Humanized Genomic Ortholog for Gene Therapy (HUGO-GT™) mouse model offers a higher degree of humanization compared to traditional models to serve as an effective evaluation platform, especially for gene therapy drugs with high requirements for gene sequence integrity, such as ASO, Targeted Gene Editing, and siRNA.

Our HUGO-GT^TM fully humanized genome mice are developed based on the proprietary TurboKnockout-Pro technology to achieve in situ replacement of mouse genes, encompassing a broader range of intervention targets and providing full coverage of pathogenic gene mutation sites-all without patent or ownership disputes. The fully humanized target genes within these models are consistent with the pathogenic genes carried by humans and cover the majority of drug targets, significantly enhancing screening efficiency for various types of preclinical drug experiments.